Search
Dexamethasone Treatment Options
A collection of 1455 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
757 - 768 of 1455
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy
Terminated
This randomized phase II trial studies how well rolapitant hydrochloride works in preventing nausea/vomiting in patients with sarcoma receiving chemotherapy. Antiemetic drugs, such as rolapitant hydrochloride, may help control or prevent nausea and vomiting in patients treated with chemotherapy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/05/2021
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Sarcoma
Emend for Multiple-day Emetogenic Chemotherapy
Completed
The purpose of the study is to assess the effect of Emend (aprepitant) on nausea and vomiting associated with chemotherapy. Chemotherapy commonly causes nausea and vomiting and this affects patients' quality of life and attitudes toward treatment. Although nausea and vomiting associated with chemotherapy has been decreasing due to improved therapy, some patients will still experience this side effect. Therefore, new medications are needed to decrease the amount of nausea and vomiting patients ha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2021
Locations: University of Illinois Medical Center, Chicago, Illinois
Conditions: Nausea, Vomiting
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
Completed
The primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and the recommended phase two dose (RPTD) of ABT-199 when administered in subjects with relapsed /refactory multiple myeloma who are receiving bortezomib and dexamethasone as their standard therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/29/2021
Locations: University of Arizona Cancer Center - North Campus /ID# 117876, Tucson, Arizona +8 locations
Conditions: Relapsed/Refractory Multiple Myeloma
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
Terminated
This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2021
Locations: Clearview Cancer Institute /ID# 156699, Huntsville, Alabama +307 locations
Conditions: Small Cell Lung Cancer
Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
Unknown
This is an investigator-initiated Phase I study of a single dose of an intravitreally-administered dexamethasone implant (Ozurdex™) in subjects with uveal melanomas (UM) and exudative retinal detachments (ERD: build-up of fluid under the retina that causes it to detach) being treated with proton beam radiation (PBI) or plaque radiotherapy. Although PBI is an effective treatment for UM, ERDs may persist after radiation, leading to vision loss. Effective treatments for ERD are currently lacking. W... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2021
Locations: i. Ocular Melanoma Center, Massachusetts Eye and Ear, Boston, Massachusetts
Conditions: Exudative Retinal Detachment and Uveal Melanoma
A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
Completed
A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2021
Locations: Advanced Vision Care, Los Angeles, California
Conditions: Anterior Chamber Inflammation, Ocular Pain, Corneal Edema, Corneal Defect, Penetrating KeratoPlasty, Nuclear Cataract, Cortical Cataract, Cataract Senile
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
Terminated
This phase I/II trial studies the side effects and the best dose of pomalidomide when given together with dexamethasone and filgrastim-sndz and to see how well they work in treating patients with multiple myeloma that has returned or that does not respond to treatment. Pomalidomide may stimulate or suppress the immune system in different ways and may stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, eithe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2021
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
Completed
Primary Objectives:
Part A: To evaluate the safety and determine the recommended dose of SAR650984 in combination with pomalidomide (P) and dexamethasone (d), in patients with Relapsed/Refractory Multiple Myeloma (RRMM).
Part B: To evaluate the feasibility of isatuximab administered from a fixed infusion volume in combination with Pd as assessed by occurrence of grade ≥3 infusion associated reactions (IAR).
Secondary Objectives:
* To evaluate the infusion duration (Part B).
* To evaluate the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2021
Locations: Investigational Site Number 840001, Scottsdale, Arizona +12 locations
Conditions: Plasma Cell Myeloma
IV Steroids Versus Steroids Included in Block for Orthopedic Lower Limb Surgery
Completed
IV and included steroids have produced the same length of block prolongation in adults as if the steroid was given with the nerve block. Clinically, this has not be noticed in children. The objective of this study is to examine this in young patients. The investigator will blindly give the steroid either in the IV or in the block solution (perineural). This is a prospective double blind study.
Gender:
ALL
Ages:
Between 5 years and 25 years
Trial Updated:
06/30/2021
Locations: Banner University Medical Center, Tucson, Arizona
Conditions: Lower Limb Injury
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
Terminated
The purpose of the study is to look at subjects who receive Lenalidomide, Dexamethasone, and Elotuzumab and determine if they will have lower surface CS1 expression on malignant plasma cells at the time of progression than those who receive Lenalidomide and Dexamethasone without Elotuzumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2021
Locations: Pacific Hematology Oncology Associates, San Francisco, California +13 locations
Conditions: Newly Diagnosed, Previously Untreated Multiple Myeloma
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
This randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
06/11/2021
Locations: Children's Hospital of Alabama, Birmingham, Alabama +235 locations
Conditions: Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
Completed
This pilot phase I trial studies the side effects and best dose of histone deacetylase (HDAC) inhibitor AR-42 (AR-42) when given together with pomalidomide in treating patients with multiple myeloma that has returned after a period of improvement. HDAC inhibitor AR-42 may work to stop cancer growth by blocking an enzyme needed for cell growth. Pomalidomide is a drug used in chemotherapy that works to stop the growth of cancer cells by causing them to die. Giving HDAC inhibitor AR-42 together wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2021
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Recurrent Plasma Cell Myeloma
757 - 768 of 1455